Taming a mutinous mutant: an errant receptor becomes a prime cancer target.
Goldman
Bruce
B
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000601:surgery / Q000628:therapy*; D019496:Cancer Vaccines; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005909:Glioblastoma / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D006801:Humans; D009154:Mutation; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D019496:Cancer Vaccines; D003606:Dacarbazine; D000077204:Temozolomide